There are limited data as how to manage the “yellow zone” in children with asthma. Although increasing the dose of inhaled corticosteroids (ICSs) has been practiced by some providers, the efficacy and safety of this strategy remain unclear. This review presents the existing data for use of adjustable dose of ICSs for prevention of asthma exacerbation in children in yellow zone. The current evidence does not support increasing the dose at early signs of loss of asthma control to prevent asthma exacerbation in children. Well-designed clinical trials are needed to identify potential benefits of this strategy.
Get full access to this article
View all access options for this article.
References
1.
Guidelines for the diagnosis and management of asthma: National Asthma Education and Prevention Program Expert Panel Report 3. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007.
2.
Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2017. www.ginasthma.org/.
3.
FitzGeraldJM, BeckerA, SearsMR, MinkS, ChungK, LeeJ, et al.Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax, 2004; 59:550–556.
4.
HarrisonTW, OborneJ, NewtonS, TattersfieldAE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet, 2004; 363:271–275.
5.
DinakarC, OppenheimerJ, PortnoyJ, BacharierLB, LiJ, KercsmarCM, et al.Management of acute loss of asthma control in the yellow zone: a practice parameter. Ann Allergy Asthma Immunol, 2014; 113:143–159.
6.
KewKM, QuinnM, QuonBS, DucharmeFM. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev, 2016; 6:CD007524.
7.
WainwrightC.A multicenter randomised controlled trial of treatment of acute exacerbations of asthma in children with a doubling of the usual inhaled corticosteroid (ICS) dose to identify efficacy of intervention. Available at: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=630 (accessed April2, 2018).
8.
GarrettJ, WilliamsS, WongC, HoldawayD. Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid. Arch Dis Child, 1998; 79:12–17.
9.
MartinezFD, ChinchilliVM, MorganWJ, BoehmerSJ, LemanskeRF, MaugerDT, et al.Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet, 2011; 377:650–657.
10.
ForesiA, MorelliMC, CatenaE. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest, 2000; 117:440–446.
11.
O'borneJ, MortimerK, HubbardRB, TattersfieldAE, HarrisonTW. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double blind, placebo controlled, parallel group, clinical trial. Am J Respir Crit Care Med, 2009; 180:598–602.
12.
Rice-McDonaldG, BowlerS, StainesG, MitchellC. Doubling daily inhaled corticosteroid dose is ineffective in mild to moderately severe attacks of asthma in adults. Intern Med J, 2005; 35:693–698.
13.
McKeeverT, MortimerK, WilsonA, WalkerS, BrightlingC, SkeggsA, et al.Quadrupling in-haled glucocorticoid dose to abort asthma exacerbations. N Engl J Med, 2018; 378:902–910.
14.
JacksonDJ, BacharierLB, MaugerDT, BoehmerS, BeigelA, ChmielJF, et al.Quintupling in-haled glucocorticoids to prevent childhood asthma exacerbations. N Engl J Med, 2018; 378:891–901.
